Myasthenia gravis (MG), an acquired autoimmune disorder of neuromuscular transmission, affects over 700,000 people worldwide.^[@R1],[@R2]^ Approximately 85% of generalized MG cases are associated with postsynaptic nicotinic acetylcholine receptor (AChR) antibodies at the motor endplate^[@R1],[@R3]^ and reduced functional AChRs.^[@R1]^ Approximately 5%--8% of patients have muscle-specific tyrosine kinase (MuSK) antibodies.^[@R4]^ Lipoprotein receptor--related protein 4 antibodies may also be clinically relevant.^[@R5],[@R6]^

Numerous (predominantly off-label) treatments are prescribed for MG, as summarized in a recent international consensus guidance statement for MG treatment by a Task Force of the Myasthenia Gravis Foundation of America.^[@R2]^ Many patients do not achieve adequate clinical response, having substantial disability despite treatment.^[@R7]^ Developing a therapy suitable for all patients is challenging due to disease heterogeneity.^[@R2]^ Acetylcholinesterase inhibitors (e.g., pyridostigmine) are considered first-line treatments for MG; however, patients with anti-MuSK antibodies often respond poorly.^[@R1],[@R8]^ Glucocorticoids or nonsteroidal immunosuppressant therapy are recommended in patients failing to meet treatment goals following an adequate pyridostigmine trial.^[@R2]^

Belimumab (Benlysta, Rockville, MD), a human immunoglobulin (Ig) G1λ monoclonal antibody against B-lymphocyte stimulator (BLyS), is licensed for adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard SLE therapy.^[@R9],[@R10]^ Elevated BLyS levels have been identified in patients with MG,^[@R11][@R12][@R13]^ highlighting it as a potential treatment target. Other monoclonal antibodies (e.g., rituximab and eculizumab) targeting different immune elements have demonstrated promising results.^[@R14][@R15][@R17]^

This study investigated the efficacy and safety of belimumab in participants with active generalized MG despite receiving standard therapy.

Methods {#s1}
=======

Study design {#s1-1}
------------

This phase II, randomized, placebo-controlled, double-blind study (BEL115123) was conducted at 13 centers in Canada, United States, Germany, and Italy between April 2013 and October 2015. Randomization was performed centrally using a computer-generated randomization schedule, created by the study statistician, stratified by antibody status. Randomization numbers were allocated to participants by an interactive voice recognition system. Blinding was maintained throughout the study until the final on-treatment assessment (week 24) for the final participant had been completed, entered into the database, and the initial database lock had been performed for the primary analysis. While the follow-up section of the study was ongoing, the results of the primary analysis were made available only to a limited group of sponsor personnel; neither the study participants nor the study site personnel were aware of results or of the treatment received. All GSK local operating companies, monitors, and investigators remained blinded until completion of the final analysis at the end of the follow-up phase (week 36). Eligible participants were randomized 1:1 to receive either IV belimumab 10 mg/kg or placebo (weeks 0, 2, 4, 8, 12, 16, and 20), and were stratified by antibody screening (AChR/MuSK). Participants were maintained on standard of care (SoC) therapies throughout. The treatment regimen was selected according to the results of 2 pivotal phase III SLE studies (BLISS-52, NCT00424476 and BLISS-76, NCT00410384).^[@R18],[@R19]^ Belimumab 10 mg/kg, administered IV, resulted in a statistically significant (BLISS-52) and numerically greater (BLISS-76) improvement in the primary efficacy endpoint (SLE Responder Index) compared with placebo by week 24.^[@R18],[@R19]^ Consequently, a 4-week screening period, 24-week treatment period, and 12-week follow-up period (during which no investigational treatment was administered) was employed for this study.

Standard protocol approvals, registrations, and participant consents {#s1-2}
--------------------------------------------------------------------

This study ([clinicaltrials.gov](http://clinicaltrials.gov) identifier NCT01480596) was performed in accordance with the International Conference for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice guidelines, the ethical procedures outlined in the Declaration of Helsinki,^[@R20]^ and applicable country-specific requirements. Written informed consent was obtained from each participant prior to any study-specific procedures.

Participants {#s2}
============

Inclusion criteria {#s2-1}
------------------

Eligible participants had generalized MG (Myasthenia Gravis Foundation of America \[MGFA\] Class II--IVa inclusive),^[@R21]^ were ≥18 years of age, were positive for AChR/MuSK antibodies, and had a Quantitative MG (QMG) score^[@R22]^ of ≥8, of which ≥4 points were derived from signs other than ocular. At entry to the study, participants must have been receiving a stable dose of one or more of the following MG treatments^[@R1]^: a cholinesterase inhibitor for a minimum of 2 weeks prior to screening and/or^[@R2]^ prednisone (minimum 1 month) and/or^[@R3]^ one of the following immunosuppressants: cyclosporine (minimum 3 months), methotrexate (minimum 3 months), azathioprine (minimum 6 months), or mycophenolate (minimum 6 months). Female participants were eligible for enrollment provided they were of nonchildbearing potential or of childbearing potential and not pregnant or nursing and agreed to several predefined criteria designed to prevent pregnancy from enrollment to 16 weeks post last dose of study treatment.

Exclusion criteria {#s2-2}
------------------

Key exclusion criteria included presence or history of thymoma, thymectomy within 12 months, and treatment with IV immunoglobulin (Ig) or plasma exchange (PLEX) within 4 weeks prior to screening or potential requirement for these treatments during the study. Participants were excluded if they had received treatment with rituximab or eculizumab within 12 months of screening, or with any other B cell--targeted therapy (including belimumab) at any time; treatment with any immunosuppressive agent other than those permitted within the inclusion criteria within 6 months; or a history of recurrent or chronic infection or currently active systemic infection.

Objectives {#s2-3}
----------

The primary objective of this study was to investigate the efficacy of belimumab vs placebo in reducing signs of MG, measured by QMG score, in participants who remained symptomatic (defined by QMG score) on SoC therapy. Secondary objectives included additional efficacy assessments, safety, and tolerability; modulation of AChR/MuSK antibody levels; and pharmacodynamic/biomarker assays. This study aimed to provide Class I evidence for the efficacy and safety of belimumab in participants with MG.

Endpoints {#s2-4}
---------

### Efficacy endpoints {#s2-4-1}

The primary endpoint was mean change from baseline in QMG score at week 24 compared with baseline. Secondary efficacy endpoints were mean change from baseline in the MG Composite Score (MGC)^[@R23]^ at week 24 and mean change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale^[@R24]^ at weeks 12 and 24. The proportion of participants with ≥3-point QMG/MGC improvement or worsening from baseline by week 24 and with a sustained improvement of ≥3 points from baseline at week 12 maintained to week 24 were also analyzed. Mean changes from baseline in QMG, MGC, and MG-ADL scores were assessed during the follow-up period at weeks 28, 32, and 36. The MGFA postintervention status,^[@R21]^ despite being a secondary efficacy endpoint, was not analyzed due to inconsistent data collection across sites.

Safety endpoints {#s2-5}
----------------

Safety endpoints (treatment and follow-up phases) included the frequency and severity of adverse events (AEs), serious AEs (SAEs), the percentage of participants with drug-related AEs, and those withdrawing due to AEs. Predefined AEs of special interest (AESI) included malignancies, hypersensitivity and infusion reactions, opportunistic infections, and suicidality. Changes from baseline, proportion of participants with values of potential clinical concern (vital signs, hematology and clinical chemistry parameters), and incidence of antibelimumab immunogenicity were assessed.

Pharmacodynamic/biomarker endpoints {#s2-6}
-----------------------------------

Change from baseline in AChR/MuSK antibody titers and in B- and T-cell counts were analyzed at weeks 8, 24, 28, and 36.

Pharmacokinetic endpoints {#s2-7}
-------------------------

Serum concentrations of belimumab were measured at day 0 and weeks 2, 8, 20, 24, and 28.

Statistical analyses {#s2-8}
--------------------

The estimated sample size was 42 participants to obtain completion of at least one postbaseline efficacy assessment by a minimum of 38 participants, providing at least 80% power to detect a treatment difference of 4.0 for the primary endpoint, assuming a SD of 4.25 utilizing *t* test methodology.

The safety population comprised all participants who had at least one infusion of the study agent. The intention-to-treat (ITT) population included all participants in the safety population who had any posttreatment efficacy assessment; this was the primary efficacy analysis population. The per protocol (PP) population was a subset of the ITT population who were not major protocol violators. The PP population was used as a sensitivity analysis, including analysis of variance on last observation carried forward (LOCF) values, for the primary endpoint only.

Change from baseline in QMG score at week 24 was analyzed using a mixed model for repeated measures (MMRM), adjusting for treatment group, visit, baseline QMG score, visit by treatment group interaction, and visit by baseline QMG score interaction. The MMRM models fitted participants as a random effect and used an unstructured covariance matrix.^[@R25]^ Given the exploratory nature of the study, Bayesian interpretation for the MMRM analysis of QMG and MGC assuming noninformative priors was also generated, and posterior probabilities that the treatment difference was \>0 were derived. A significant *p* value from a frequentist 2-sided test at the 5% level (*p* \< 0.05) is equivalent to the posterior probability exceeding 0.975 (i.e., statistical significance occurs at the α% level for a 2-sided test with no multiplicity adjustment when the PP exceeds 1 − (\[α/100\]/2).^[@R26]^

Secondary efficacy analyses of continuous data were performed using similar MMRM methods as the primary analysis. Analyses comparing the proportion of participants were planned for Cochran-Mantel-Haenszel χ^2^ analyses using the observed data, where missing data were assumed to be a negative response. Due to very low response rates, proportions of participants improving or worsening were analyzed using exact methodology with tests stratified by the observed median baseline score (≤ median, \> median).

Results {#s3}
=======

Study population and participant disposition {#s3-1}
--------------------------------------------

Forty participants were randomized (belimumab n = 18; placebo n = 22) ([figure 1](#F1){ref-type="fig"})*.* Demographic characteristics and baseline medical and MG history were balanced between the treatment groups. Baseline MG severity, measured by QMG, MGC, and MG-ADL, were in the mild to moderate range; median QMG scores (range) were 12.00 (8.0, 19.5) and 12.50 (6.50, 23.0) for belimumab and placebo, respectively ([table 1](#T1){ref-type="table"}). Participants were predominantly female (62%) with a mean (SD) age of 56.1 (15.67) years, and a mean (SD) MG symptom duration of 9.0 (8.13) (placebo) or 8.7 (9.00) (belimumab) years. Most participants had AChR antibodies; 2 participants, both in the placebo group, had MuSK antibodies.

![CONSORT diagram](NEUROLOGY2017817734FF1){#F1}

###### 

Demographic baseline characteristics, myasthenia gravis (MG) history, baseline MG disease, and concomitant MG medications taken during the treatment phase (intention-to-treat population)
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Efficacy {#s3-2}
--------

The primary endpoint, QMG mean change (standard error) from baseline at week 24, was −4.21 (1.14) compared with −2.37 (1.10) for placebo ([figure 2A](#F2){ref-type="fig"}). However, the treatment difference (1.84 points) was not statistically significant (*p* = 0.256) ([table 2](#T2){ref-type="table"}). Nevertheless, posterior probability analysis did indicate a signal of potential efficacy (posterior probability \>0.8). Further comparisons of belimumab vs placebo were made for QMG mean change from baseline at week 24 to assess the sensitivity of the analyses to the effects of protocol violations and missing data. These analyses (PP population and LOCF) also demonstrated no significant difference between belimumab and placebo (*p* = 0.267 and 0.187, respectively) ([table 2](#T2){ref-type="table"}). A change of ≥3 points in QMG score was seen in 61% of belimumab participants vs 29% of placebo participants (*p* = 0.082), while only 44% vs 24%, respectively (*p* = 0.184), demonstrated a sustained change of ≥3 points.

![Adjusted mean change from baseline in Quantitative Myasthenia Gravis (QMG), Myasthenia Gravis Composite (MGC), and Myasthenia Gravis Activities of Daily Living (MG-ADL) (mixed model for repeated measures \[MMRM\])\
(A) QMG. (B) MGC. (C) MG-ADL (MMRM). Data represent the intention-to-treat (ITT) population. Negative score is indicative of an improvement. The MMRM analysis method was adjusted for treatment and visit baseline scale score, treatment by visit, and baseline scale score by visit. The QMG score at baseline is the average of the screening and week 0 baseline scores. The MGC and MG-ADL score at baseline was the week 0 baseline score. CI = confidence interval.](NEUROLOGY2017817734FF2){#F2}

###### 

Mixed model for repeated measures (MMRM) analysis of change from baseline in Quantitative Myasthenia Gravis (QMG), Myasthenia Gravis Composite (MGC), and Myasthenia Gravis Activities of Daily Living (MG-ADL) at weeks 24 and 36, and proportion of participants with improved, worsening, or sustained improvement in QMG/MGC scores at week 24

![](NEUROLOGY2017817734TT2)

![](NEUROLOGY2017817734TT2A)

There was no difference between the 2 treatment groups for the mean change from baseline in MGC or MG-ADL score at week 24 or at week 36; the MGC and MG-ADL scores decreased by a similar amount in both groups ([figure 2, B and C](#F2){ref-type="fig"}). The proportion of participants improving by ≥3 points in MGC score was similar in both placebo (48%) and belimumab (50%) groups. A greater proportion of belimumab (39%) than placebo (19%) participants had a sustained improvement; this was not statistically significant (*p* = 0.175). Slightly more participants worsened (≥3 points) in placebo vs belimumab (24% vs 11%, respectively; *p* = 0.530).

Safety {#s3-3}
------

A similar proportion of participants reported AEs in the belimumab (78%) and placebo (91%) groups during the treatment phase ([table 3](#T3){ref-type="table"}). The most common were influenza and nausea (belimumab group) and diarrhea, back pain, and headache (placebo group). Treatment-related AEs were similar across groups: 32% (placebo) and 28% (belimumab). Five SAEs (nephrolithiasis, sepsis, ruptured aortic dissection, MG exacerbation, and cholelithiasis) were reported in 4 (18%) participants in the placebo group only. The MG exacerbation was treated with PLEX; this participant was withdrawn from the study. Severe AEs occurred in 5 (23%) participants receiving placebo and 1 (6%) participant in the belimumab group. One participant receiving placebo died due to severe sepsis; concomitant medications for this participant included azathioprine. Twelve participants in the placebo (55%) and belimumab (67%) groups experienced AEs during the follow-up phase, with severe AEs reported in 1 (5%) participant receiving placebo and 3 (17%) participants receiving belimumab. Three participants (placebo group) had AEs that led to withdrawal from the study; all were classified as SAEs. No deaths occurred during follow-up.

###### 

Participants reporting adverse events (AEs) during the study (safety population)

![](NEUROLOGY2017817734TT3)

AESI were reported in 5 (23%) and 4 (22%) participants (treatment phase) in the placebo and belimumab groups, respectively; the most common events were postinfusion systemic reactions. No malignancies, opportunistic infections, or suicidality events were reported in the study. Clinical chemistry, hematology, liver function, and vital sign measurements revealed no findings of clinical relevance.

Pharmacodynamic/biomarker results {#s3-4}
---------------------------------

Two participants with MuSK antibodies were identified (placebo group); all other participants had AChR antibodies. A small decrease in AChR antibody titers occurred in both treatment groups during the treatment phase; these returned to baseline levels during follow-up (figure e-1A, [links.lww.com/WNL/A370](http://links.lww.com/WNL/A370)). No relationship was observed between efficacy and percentage change in antibody levels from baseline to week 24 (overall correlation coefficients: QMG −0.025; MGC −0.090) (figure e-1, B and C).

Pharmacokinetics results {#s3-5}
------------------------

Pharmacokinetic results are presented in table e-1 ([links.lww.com/WNL/A371](http://links.lww.com/WNL/A371)). Steady-state belimumab concentrations were reached early in the trial and maintained throughout the treatment period.

Discussion {#s4}
==========

This phase II study evaluated the efficacy and safety of belimumab in participants with generalized MG who remained symptomatic while on SoC therapy. The primary endpoint (mean change from baseline in the QMG score at week 24) was not met. Although the data showed a small numerical improvement in favor of belimumab, this was not statistically significant and the treatment difference of ∼2 points was below that considered to be clinically meaningful (3--4 points).^[@R27]^ In this study, posterior probability analysis indicated a signal of potential efficacy (posterior probability \>0.8). Further analysis of the QMG scale data showed that, while not statistically significant, a higher proportion of participants improved with belimumab treatment compared with placebo at week 24, and demonstrated sustained improvement from weeks 12--24. This endpoint has been widely used in nonregulatory MG clinical trials and provides a validated measure of muscle strength.^[@R22],[@R27]^

There was no difference between belimumab and placebo for mean change from baseline for MGC and MG-ADL (week 24 and 36). Mean change from baseline in QMG score, and the proportion of participants improving as measured by QMG, demonstrated a slight numerical improvement over placebo. Overall, the QMG, MGC, and MG-ADL scales all indicated a lack of belimumab effect. The MGC, a validated MG rating scale recommended by the MGFA taskforce,^[@R28]^ differs from the QMG in 2 key aspects: (1) it is a weighted scale where symptoms considered to have a greater effect on the patient are given a higher score; (2) it takes into account the patient\'s own view of his or her symptoms. The QMG, by contrast, is entirely physician-assessed and scores all symptoms on the same scale^[@R22]^; such differences may explain the slight improvement observed in the QMG score compared with either MGC or MG-ADL.

Belimumab serum concentrations were as expected based on prior clinical experience in 2 phase III registration studies in SLE.^[@R29]^ Decreased naive B-cell and increased memory B-cell counts were seen following belimumab treatment; given the inhibitory effect of belimumab on B cells, this was not unexpected and has previously been reported in SLE.^[@R9]^ No correlation between efficacy (QMG or MGC) and change in antibody levels was seen. Longer periods of time may be required to observe alterations in antibody level; some autoantibodies require 1--2 years of belimumab treatment to be significantly reduced.^[@R30]^ In addition, peripheral antibody titers may not be a valid marker of the neuromuscular junction process. This lack of correlation is consistent with previous observations in MG.^[@R27],[@R31]^

The safety profile for belimumab was consistent with that seen in SLE studies; no new safety signals were identified in this generalized MG population and only one death was reported (placebo group).^[@R18],[@R32]^

This study has several limitations. Participants recruited were already receiving SoC therapy. The mild level of severity in the population studied here may have contributed to scale insensitivity and floor effects (i.e., the lower limits of the QMG scale were higher than the corresponding disease severity). Participants recruited for the current study may have achieved a symptom plateau, thus reducing the likelihood of further improvement with belimumab. A prior study of patients with more severe MG (QMG baseline score of ≥12) did identify a response to eculizumab treatment.^[@R17]^ The inclusion of participants with more severe MG may have resulted in an improved outcome. Lack of MuSK participants may have contributed to the lack of efficacy. Indeed, case studies with B-cell-targeting rituximab have reported improved and longer-lasting clinical benefit in patients with MuSK MG than those with AChR antibodies.^[@R15]^ Finally, this was a small study (n = 40); as such, considerable variability in the dataset may be expected, with small participant numbers driving the observations seen.

Several emerging therapies for MG have shown promising results. Rituximab, which targets B cells, albeit differently from belimumab, has demonstrated improved clinical outcomes and reduced immunotherapy requirements in a number of retrospective case studies of MG.^[@R14][@R15][@R16],[@R33],[@R34]^ No published, adequately powered, randomized, controlled trials of rituximab in MG currently exist. Eculizumab, a humanized monoclonal antibody that blocks complement activation, has shown significant clinical benefit for the improvement of MG compared with placebo in a small (n = 14) randomized phase II study.^[@R17]^ In a larger (n = 125) phase III study of patients with an MG-ADL total score ≥6 who had previously failed treatment, the primary endpoint, change in MG-ADL, did not reach statistical significance. Statistical significance was achieved for several prespecified analyses.^[@R35]^

This study did not meet its primary endpoint and belimumab demonstrated no significant efficacy compared with placebo in participants with generalized MG who were receiving SoC treatments.
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